title: Clozaril. An Australian experience.
abstract: 1. Clozaril, an atypical antipsychotic, did not gain approval for use in Australia until 1992. Prior to its general release, a trial was conducted in three pilot sites to test the efficacy of a monitoring system. 2. Fear of litigation among hospital staff was reduced through educational sessions that reported on the low incidence of serious side effects and the efficacy of the monitoring system. 3. The most common side effect noted with initiation of Clozaril was sedation, which persisted for 4 to 6 weeks. Subsequent side effects included drowsiness, increased salivation, and tachycardia.
authors.affiliation: Clinical Studies Unit, Wolston Park Hospital, Wacol, Queensland, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Chatterton
mesh_terms: D001291:Attitude of Health Personnel; D001315:Australia; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D003431:Cross-Cultural Comparison; D016903:Drug Monitoring; D006801:Humans; D009730:Nursing Assessment; D010348:Patient Care Team; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000451:nursing / Q000523:psychology
chemical_list: D003024:Clozapine